NOTVQ (Inotiv) EBITDA per Share: $0.20 (TTM As of Mar. 2026)


What is Inotiv EBITDA per Share?

Inotiv NOTVQ -9.91% EBITDA per Share is $0.20 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 171 Medical Diagnostics & Research companies, Inotiv ranks worse than 584794.74% on this metric.

Inotiv's EBITDA per Share for the three months ended in Mar. 2026 was $-0.16. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.20.

During the past 12 months, the average EBITDA per Share Growth Rate of Inotiv was 71.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Inotiv's EBITDA per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Inotiv was 96.60% per year. The lowest was -61.60% per year. And the median was 0.50% per year.

NOTVQ's 3-Year EBITDA Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 10.6
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Inotiv's EBITDA for the three months ended in Mar. 2026 was $-5.6 Mil.

During the past 12 months, the average EBITDA Growth Rate of Inotiv was 21.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Inotiv was 113.00% per year. The lowest was -61.80% per year. And the median was 1.65% per year.


Inotiv  (OTCPK:NOTVQ) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Inotiv EBITDA per Share Related Terms


Inotiv EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Inotiv's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inotiv EBITDA per Share Chart

Inotiv Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.02 -11.23 -1.03 -1.03 0.76

Inotiv Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.26 0.19 -0.08 -0.16

Inotiv EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Inotiv's EBITDA per Share for the fiscal year that ended in Sep. 2025 is calculated as

EBITDA per Share(A: Sep. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=24.753/32.452
=0.76

Inotiv's EBITDA per Share for the quarter that ended in Mar. 2026 is calculated as

EBITDA per Share(Q: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=-5.599/34.653
=-0.16

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of $0.20 mean?
Inotiv (NOTVQ) has a EBITDA per Share of $0.20 as of Mar. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Inotiv and its competitors. According to the industry distribution chart, Inotiv ranks #999999 out of 171 companies in the Medical Diagnostics & Research industry.
Is Inotiv's EBITDA per Share too high?
Inotiv's current EBITDA per Share is $0.20. The Medical Diagnostics & Research industry median EBITDA per Share is 10.60. Inotiv's value of $0.20 is 98.1% below this industry median. Based on the distribution chart, Inotiv ranks #999999 out of 171 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Inotiv's EBITDA per Share compare to NDRA and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Inotiv ranks #999999 out of 171 companies for EBITDA per Share. This places Inotiv in the lower half of its industry. The industry median EBITDA per Share is 10.60. Inotiv's value of $0.20 is 98.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Medical Diagnostics & Research company?
The median EBITDA per Share among Medical Diagnostics & Research companies is 10.60, based on 171 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inotiv's current EBITDA per Share of $0.20 is 98.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Inotiv and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA per Share is 10.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inotiv's current EBITDA per Share is $0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (NOTVQ) is currently considered Possible Value Trap. The stock's GF Value™ is $1.68, compared to a current price of $0.01 — trading 99.4% below its estimated fair value. The current EBITDA per Share is $0.20 and 98.1% below the Medical Diagnostics & Research industry median of 10.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Inotiv (NOTVQ), the current EBITDA per Share is $0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inotiv Business Description

Other Exchanges BS50:Germany
Address 2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.